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geon and to the interventional cardiologist. Regarding the
combination of MLR and conventional bypass operations,
Allen and associates1 recently presented favorable results of a
multicenter prospective randomized study; therefore we agree
that the combination of revascularization techniques using
minimally invasive off-pump surgery and MLR (percuta-
neous or surgical) will have a role in the future for selected
subsets of patients. This multimodality collaborative approach
to myocardial revascularization is currently being applied
increasingly at our institution, and we agree with Mack’s
recent forecast2 that in 10 years 50% of all cardiac operations
will be combined with a catheter-based procedure. To quote
Rihal and Yusuf,3 perhaps the relevant clinical question is not
which mode of treatment is best, but which combinations of
treatments, in what sequence, are appropriate for a specific
patient at a specific point in his or her clinical course.
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Aortic arch reconstruction without circulatory
arrest
To the Editor:
We read with great interest the discussion of a modified
perfusion technique during Norwood reconstruction by
Pigula, Siewers, and Nemoto1 and can offer some modifica-
tions that will further improve on this technique. In their
report, the authors describe a technique to provide regional
cerebral perfusion through the distal end of a partially con-
structed 3.5-mm polytetrafluoroethylene shunt to provide
cerebral flow through the innominate artery during the “cir-
culatory arrest” period. The authors monitor regional cerebral
oxyhemoglobin saturation and relative cerebral blood volume
index and demonstrate that the collateral network provides
seemingly adequate cerebral blood flow while the arch is
being reconstructed. Further supporting the presence of an
extensive collateral network, the authors note the need for an
aortic crossclamp on the distal aorta to prevent the collateral
flow from flooding the operative field.
We have used a similar technique for Norwood-type recon-
struction in hypoplastic left heart syndrome and describe
some differences in technique that offer further benefit. In
contrast to Pigula, Siewers, and Nemoto, our first maneuver
after a short period of surface cooling (to 34°C), sternotomy,
and heparinization is to create the proximal end of a 3.5-mm
polytetrafluoroethylene shunt at the base of the right subcla-
vian artery. This shunt is left long and is cannulated with the
arterial inflow cannula (8F, Research Medical, Inc, Salt Lake
City, Utah). Cardiopulmonary bypass is then initiated with
bicaval venous cannulation and the pulmonary arteries are
controlled with snares. The patient is cooled to 18°C over 20
minutes.
The advantage of this modification in technique is that a
large portion of the procedure can then be performed during
full cardiopulmonary bypass while cooling. Specifically,
using the shunt as the arterial inflow leaves the aortic arch
and ductus arteriosus free of cannulas. Consequently, the
ductus can be ligated and divided, after which the main pul-
monary artery can be divided and the pulmonary artery defect
closed with a small polytetrafluoroethylene patch.
Furthermore, the right atrium can then be opened and the atri-
al septectomy performed. There is no possibility of ejecting
air in cases of aortic atresia due to the valve atresia and the
fact that the main pulmonary artery is divided. By this time,
the patient has been nearly completely cooled to 18°C. A
“drop in” sucker can be left in the right atrium to keep the
field clear.
Up to this point, the patient has been maintained on full
cardiopulmonary bypass without any myocardial ischemia.
Flow can be momentarily interrupted and cardioplegic solu-
tion infused through the arterial inflow cannula with the
descending aorta clamped and the subclavian and carotid
arteries temporarily occluded. Cardiopulmonary bypass is
then resumed at 30 to 60 mL/min with the base of the innom-
inate artery occluded and the distal subclavian and right
carotid artery snares released. We monitor pressure in the
right radial artery and maintain it at 20 to 30 mm Hg. The
arch reconstruction is then completed and, like Pigula,
Siewers, and Nemoto, we use a crossclamp on the distal aorta
to avoid collateral flow from obscuring the operative field.
On completion of the arch reconstruction, the neo-aortic
arch is cannulated with a second cannula and the arch
deaired. Arterial inflow is then transferred to the new cannu-
la and full cardiopulmonary bypass resumed. While the
patient is being rewarmed, the distal end of the 3.5-mm shunt
is trimmed and an anastomosis completed with the right pul-
monary artery.
The chief advantage of these modifications is better time
efficiency during the case. All the portions of the repair outside
the aortic arch are performed during the cooling period with
full cardiopulmonary bypass and without cardioplegic arrest.
Myocardial ischemia and regional cerebral perfusion are limit-
ed to only the period during which the ascending aorta is open.
This shortened period of systemic “circulatory arrest” aug-
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mented with regional cerebral perfusion may provide better
cerebral protection than more conventional techniques.
Although the data presented by Pigula, Siewers, and
Nemoto are suggestive of adequate cerebral protection, we
still believe that core cooling to 18°C is the principal compo-
nent of our cerebral protection strategy. Further study is war-
ranted to ascertain the relative merits of regional cerebral per-
fusion versus hypothermia for cerebral protection during
aortic arch reconstruction in the neonate. 
Christopher A. Caldarone, MD
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Drug therapy before coronary artery operations
To the Editor:
We were greatly interested by the results of the IMAGE
trial,1 which suggests European patients are more susceptible
than US patients to aprotinin-induced vein graft occlusion.
This has prompted us to inquire whether our patients have a
European or US response to aprotinin.
We have used aprotinin in varying doses for patients under-
going redo operations or for those with recent aspirin inges-
tion. Table I describes our mortality rate in consecutive
patients undergoing coronary artery bypass grafting with or
without other procedures between 1993 and 1998; a dose-
dependent increase in mortality is evident. However, the indi-
cations for aprotinin are also very important risk factors for
perioperative mortality. Thus it may not be too surprising that
patients given aprotinin have a higher mortality rate. To clar-
ify this, we have further analyzed our data to take risk factors
for mortality into account.
The patients and model have been described in detail else-
where.2 Logistic regression was performed with in-hospital
mortality from any cause as the dependent factor and 22 inde-
pendent factors: age, sex, urgency of the operation, history of
cardiac surgery, concurrent cardiac or cardiovascular proce-
dures, left ventricular function, recent myocardial infarct, left
main coronary artery stenosis, chronic airways disease, cere-
brovascular disease, diabetes, hypertension, and other risk
factors including preoperative cardioactive drug use.
Stepwise regression was not used.
In this model we found the relative risk of mortality attrib-
utable to aprotinin to be 1.34 per million units of aprotinin
with 95% confidence intervals of 1.1 to 1.7 (P = .01 for rela-
tive risk = 1). This indicates a risk-adjusted association
between aprotinin and in-hospital mortality.
In the jargon of evidence-based medicine, our data are
“class III evidence” and should not be considered conclusive.
However, taken in conjunction with the IMAGE trial results,
our data support the hypothesis that in some circumstances
aprotinin may have a deleterious effect on patients undergo-
ing coronary artery operations.
We do not understand why aprotinin appears to have
adverse effects in some surgical units and not others. We use
balanced salt solutions for vein distention, maintain kaolin-
activated clotting times above 600 seconds, and never admin-
ister our blood cardioplegic solution through vein grafts.
Until it becomes clear why the adverse effects of aprotinin
appear to be site specific, we would suggest that aprotinin
should be used with caution in coronary artery operations.
William M. Weightman, MB, ChB
M. A. J. Newman, MD
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Reply to the Editor:
The letter by Weightman and Newman suggests a dose-
dependant mortality for aprotinin doses ranging from 0 to
‡ 4,000,000 KIU (see their Table I). In the IMAGE study (J
Thorac Cardiovasc Surg 1998;116:716-30), the average dose
in aprotinin-treated patients was 5,550,000 KIU (n = 436).
This total includes the 2,000,000 KIU loading dose,
2,000,000 KIU into the cardiopulmonary bypass circuit
prime, plus 1,570,000 KIU by continuous infusion at a pre-
scribed rate of 500,000 KIU per hour. IMAGE study results
showed that this administration regimen for aprotinin had no
effect on mortality (placebo, 1.6%; aprotinin, 1.4%). In the
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Table I. Dose of aprotinin, number of patients, and
in-hospital mortality rate for 1593 consecutive
patients undergoing coronary artery operations
Dose of aprotinin Mortality rate 
(106 KIU) n (%)
0 839 1.8
<1 248 3.2
1-1.9 191 3.1
2-2.9 201 6.5
3-3.9 62 9.7
‡ 4 52 11.5
